COFCO Biotechnology Co., Ltd. (SHE:000930)
China · Delayed Price · Currency is CNY 6.31
-0.43 (-6.38%)
At close: Feb 2, 2026
COFCO Biotechnology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 17,913 | 19,776 | 20,064 | 19,619 | 23,560 | 19,257 |
Other Revenue | 277.71 | 277.71 | 314.46 | 299.42 | - | 652.13 |
| 18,191 | 20,053 | 20,379 | 19,918 | 23,560 | 19,909 | |
Revenue Growth (YoY) | -12.47% | -1.60% | 2.31% | -15.46% | 18.33% | 2.25% |
Cost of Revenue | 17,056 | 18,908 | 19,798 | 17,837 | 21,122 | 18,089 |
Gross Profit | 1,135 | 1,146 | 581.4 | 2,081 | 2,437 | 1,821 |
Selling, General & Admin | 780.06 | 826.35 | 789.39 | 807.17 | 814.69 | 798.78 |
Research & Development | 155 | 128.83 | 165.28 | 132.86 | 119.28 | 113.67 |
Other Operating Expenses | 75.71 | 32.13 | 46.61 | -386.92 | -181.36 | 109.04 |
Operating Expenses | 1,048 | 1,023 | 1,001 | 553.32 | 752.82 | 1,021 |
Operating Income | 87.41 | 122.44 | -419.74 | 1,527 | 1,684 | 799.23 |
Interest Expense | -96.77 | -104.86 | -112.78 | -87.12 | -157.79 | -94.32 |
Interest & Investment Income | 64.57 | 70.96 | 38.77 | 16.24 | 55.51 | 10.58 |
Currency Exchange Gain (Loss) | -1.36 | -1.36 | 10.85 | 65.92 | -1.22 | -3.33 |
Other Non Operating Income (Expenses) | 7.13 | 10.73 | -6.76 | -15.06 | 15.08 | -14.31 |
EBT Excluding Unusual Items | 60.98 | 97.91 | -489.66 | 1,507 | 1,596 | 697.86 |
Gain (Loss) on Sale of Investments | 39.14 | -8.13 | -32.93 | -4.26 | 1.86 | -23.54 |
Gain (Loss) on Sale of Assets | 30.15 | -0.15 | 1.16 | -145.82 | -203.22 | -13.98 |
Asset Writedown | -37.38 | -2.27 | -54.45 | -13.3 | -21.48 | -27.07 |
Other Unusual Items | 26.29 | 11.03 | -0.24 | 5.25 | -5.18 | 164.7 |
Pretax Income | 150.19 | 129.4 | -542.54 | 1,360 | 1,377 | 801.95 |
Income Tax Expense | 43.23 | 83.7 | 73.75 | 299.28 | 247.88 | 173.75 |
Earnings From Continuing Operations | 106.96 | 45.7 | -616.29 | 1,061 | 1,130 | 628.2 |
Minority Interest in Earnings | -12.25 | -20.57 | 14.66 | -2.08 | 0.09 | -35.08 |
Net Income | 94.71 | 25.13 | -601.63 | 1,059 | 1,130 | 593.12 |
Net Income to Common | 94.71 | 25.13 | -601.63 | 1,059 | 1,130 | 593.12 |
Net Income Growth | - | - | - | -6.29% | 90.45% | 0.05% |
Shares Outstanding (Basic) | 1,867 | 1,861 | 1,842 | 1,857 | 1,844 | 1,848 |
Shares Outstanding (Diluted) | 1,867 | 1,861 | 1,842 | 1,857 | 1,849 | 1,852 |
Shares Change (YoY) | 0.72% | 1.08% | -0.85% | 0.45% | -0.18% | 0.27% |
EPS (Basic) | 0.05 | 0.01 | -0.33 | 0.57 | 0.61 | 0.32 |
EPS (Diluted) | 0.05 | 0.01 | -0.33 | 0.57 | 0.61 | 0.32 |
EPS Growth | - | - | - | -6.71% | 90.79% | -0.22% |
Free Cash Flow | 645.46 | -327.49 | 1,323 | 142.66 | 3,732 | -3,898 |
Free Cash Flow Per Share | 0.35 | -0.18 | 0.72 | 0.08 | 2.02 | -2.10 |
Dividend Per Share | - | - | - | 0.570 | 0.245 | 0.065 |
Dividend Growth | - | - | - | 132.65% | 276.92% | 306.25% |
Gross Margin | 6.24% | 5.71% | 2.85% | 10.45% | 10.35% | 9.14% |
Operating Margin | 0.48% | 0.61% | -2.06% | 7.67% | 7.15% | 4.01% |
Profit Margin | 0.52% | 0.13% | -2.95% | 5.31% | 4.79% | 2.98% |
Free Cash Flow Margin | 3.55% | -1.63% | 6.49% | 0.72% | 15.84% | -19.58% |
EBITDA | 579.95 | 603.97 | 47.11 | 1,967 | 2,119 | 1,236 |
EBITDA Margin | 3.19% | 3.01% | 0.23% | 9.88% | 9.00% | 6.21% |
D&A For EBITDA | 492.54 | 481.53 | 466.84 | 439.53 | 434.94 | 436.4 |
EBIT | 87.41 | 122.44 | -419.74 | 1,527 | 1,684 | 799.23 |
EBIT Margin | 0.48% | 0.61% | -2.06% | 7.67% | 7.15% | 4.01% |
Effective Tax Rate | 28.79% | 64.68% | - | 22.01% | 18.00% | 21.67% |
Revenue as Reported | 18,191 | 20,053 | 20,379 | 19,918 | 23,560 | 19,909 |
Advertising Expenses | - | 0.44 | 3.04 | 2.81 | 2.68 | 4.13 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.